PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 154 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 1.56 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $150,000 | -11.8% | 18,678 | -17.9% | 0.05% | +17.1% |
| Q1 2018 | $170,000 | +70.0% | 22,749 | +35.8% | 0.04% | +41.4% |
| Q4 2017 | $100,000 | -70.1% | 16,750 | -66.0% | 0.03% | -75.0% |
| Q2 2017 | $335,000 | +82.1% | 49,300 | +152.4% | 0.12% | +54.7% |
| Q1 2017 | $184,000 | +78.6% | 19,532 | +64.1% | 0.08% | +38.9% |
| Q4 2016 | $103,000 | – | 11,900 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |